The Cooper Companies, Inc. (NASDAQ:COO) Position Increased by LPL Financial LLC

LPL Financial LLC lifted its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 12.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 141,604 shares of the medical device company’s stock after buying an additional 15,746 shares during the quarter. LPL Financial LLC owned approximately 0.07% of Cooper Companies worth $13,018,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of COO. Raymond James Financial Inc. bought a new position in Cooper Companies in the fourth quarter worth about $64,826,000. Victory Capital Management Inc. lifted its holdings in shares of Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after purchasing an additional 574,899 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Cooper Companies by 13.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock worth $543,979,000 after purchasing an additional 573,908 shares during the last quarter. Wealthfront Advisers LLC grew its stake in Cooper Companies by 4,594.1% during the 4th quarter. Wealthfront Advisers LLC now owns 569,812 shares of the medical device company’s stock worth $52,383,000 after buying an additional 557,673 shares during the last quarter. Finally, Alecta Tjanstepension Omsesidigt acquired a new stake in Cooper Companies in the fourth quarter worth $49,550,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on COO. Robert W. Baird lowered their price target on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. JPMorgan Chase & Co. dropped their price target on shares of Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Morgan Stanley cut their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Citigroup decreased their price objective on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday, March 7th. Finally, Wells Fargo & Company lifted their target price on Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Stock Down 0.0 %

COO opened at $81.23 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The company has a market capitalization of $16.24 billion, a PE ratio of 41.66, a P/E/G ratio of 2.25 and a beta of 1.02. The stock’s fifty day moving average is $88.59 and its 200-day moving average is $96.72. The Cooper Companies, Inc. has a one year low of $77.05 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. On average, equities analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.